Could a common amyloidosis drug help after a heart transplant?
NCT ID NCT05489523
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This study tests whether tafamidis, a drug that stabilizes a protein called transthyretin, is safe and effective in 25 people who have had a heart transplant for ATTR amyloidosis. Participants take tafamidis daily for 12 months. The goal is to see if it can slow or prevent amyloid buildup in nerves and the gut, which often continues after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN CARDIAC AMYLOIDOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cedars-Sinai
Beverly Hills, California, 90211, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tafamidis
What this could lead to
If it works, tafamidis could help prevent worsening nerve and gut problems in people who have had a heart transplant for ATTR amyloidosis.
What could go wrong
This is a small, single-arm study with only 25 participants, so results may not apply broadly. Tafamidis is already approved for ATTR, but its benefit after transplant is unproven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.